Drug Profile
ACE 393
Alternative Names: ACE-393; Campylobacter jejuni vaccine - ZymenexLatest Information Update: 21 Mar 2014
Price :
$50
*
At a glance
- Originator ACE BioSciences
- Developer ACE BioSciences; Naval Medical Research Center
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Campylobacter infections
Most Recent Events
- 21 Mar 2014 Discontinued - Phase-II for Campylobacter infections in USA & Phase I for Campylobacter infections in France (IM)
- 18 Jan 2011 No development reported - Phase-II for Campylobacter infections in USA (IM)
- 09 Nov 2009 ACE BioSciences has been acquired by Zymenex A/S